Evaluation of nitric oxide as a novel diagnostic marker for hepatocellular carcinoma

IntroductionLiver cancer is the sixth most common cancer worldwide. HCC is the most common primary tumor of the liver. The National Comprehensive Cancer Network (NCCN) clinical practice guidelines for treatment of hepatobiliary cancers propose surveillance for the early detection of HCC by liver ultrasonography every 3–6 months and evaluation of AFP. AFP >200 ng/ml is considered diagnostic for HCC, although fewer than half of patients of HCC may generate levels that are high, so that the specificity of AFP is close to 100% but the sensitivity is 45%. Nitrite/Nitrate is a stable end product of nitric oxide increase in patients with HCC.AimIt was to evaluate nitric oxide as a novel diagnostic marker for hepatocellular carcinoma.MethodsEighty patients and 15 normal individuals enrolled in the study: Group (1) 15 normal individuals. Group (2) 30 patients with chronic liver disease without HCC. Group (3) 50 patients with HCC. History taking, clinical examination, (detection of liver masses, ascites, spleen size, and grade of encepathalopathy), and Child-pugh scoring. Laboratory investigation: (AlT, AST, bilirubin, albumin, prothrombin, GGT, platelet count, AFP, nitric oxide, HBs-Ag, and HCV-Ab). Abdominal ultrasonography and spiral CT.ResultsThe median level of nitric oxide was significantly higher in Group (3) (170 μmol/l) than in Group (2) (56 μmol/l) than in Group (1) (22 μmol/l), with a sensitivity of (68%) and specificity of (90%) at a cutoff level of 110 μmol/l and area under the curve of (0.810).While AFP, at a cutoff level of 200 ng/ml had a sensitivity of (52%), specificity of (100%) and area under the curve (0.855). Indeed nitric oxide was high in 42% of AFP-negative HCC patients.ConclusionNitric oxide is a novel diagnostic marker for hepatocellular carcinoma, the simultaneous determination of serum nitric oxide and AFP gave significant improvement in detection of HCC patients compared to that of AFP alone.